Células CAR-NK: Un modelo para la inmunoterapia tumoral. Revisión de la literatura

Autores/as

Palabras clave:

Células asesinas naturales, Receptores quiméricos de antígenos, Inmunoterapia, Tumor, Cáncer

Resumen

El objetivo de esta revisión es describir los principios biológicos, inmunológicos, y oncológicos que, están asociados, con la fundamentación teórica de la utilización de las células CAR-NK, para la inmunoterapia tumoral. Desde el descubrimiento de las células asesinas naturales (en inglés Natural Killer Cells o células NK), se han presentado grandes avances en la comprensión de los mecanismos acción, y sus funciones relacionadas con el sistema inmunológico. Este conocimiento ha dado paso al desarrollo de las tecnologías y terapias prometedoras, como las basadas en las células NK modificadas genéticamente con los receptores quiméricos de antígenos (en inglés Chimeric Antigen Receptors o CAR) denominadas, por sus siglas en inglés, células CAR-NK que originalmente fueron diseñadas, para el tratamiento de diferentes tipos de cáncer, mostrando resultados potenciales en modelos animales. Se espera que los ensayos clínicos que se están desarrollando arrojen resultados positivos de las células CAR-NK, permitiendo conocer las ventajas y desventajas de este tipo de inmunoterapia.

Biografía del autor/a

John Darowin Betancourt-Plaza, Pontificia Universidad Javeriana Cali (Colombia)

Estudiante de medicina, Semillero de Innovadores en Salud ISSEM.

José Guillermo Ortega-Ávila, Pontificia Universidad Javeriana Cali (Colombia)

Bacteriólogo Clínico, Doctor en Ciencias Biomédicas, Profesor Departamento de Ciencias Básicas de la Salud.

Citas

Dobosz P, Dzieciątkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019; 10(2965):1-10. DOI: 10.3389/fimmu.2019.02965

Ortiz-Lazo E, Arriagada-Egnen C, Poehls C, Concha-Rogazy M. An Update on the Treatment and Management of Cellulitis. Actas Dermosifiliogr. 2019; 110(2):124-130. DOI: 10.1016/j.adengl.2019.01.011

Decker W, da Silva R, Sanabria M, Angelo L, Guimarães F, Burt B, et al. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2017;8(829):1-13. DOI: 10.3389/fimmu.2017.00829

Tan S, Li D, Zhu X. Cancer Immunotherapy: Pros, cons and beyond. Biomedicine & Pharmacotherapy. 2020; 124(109821):1-11. DOI: 10.1016/j.biopha.2020.109821

Riley R, June C, Langer R, Mitchell M. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18:175-196. DOI: 10.1038/s41573-018-0006-z

Hegde P, Chen D. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020; 52(1):17-35. DOI: 10.1016/j.immuni.2019.12.011

Xie G, Dong H, Liang Y, Ham J, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020; 59(102975):1-10. DOI: 10.1016/j.ebiom.2020.102975

Abel A, Yang C, Thakar M, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9(1869):1-23. DOI: 10.3389/fimmu.2018.01869

Bi J, Wang X. Molecular Regulation of Nk Cell Maturation. Front Immunol. 2020; 11(1945):1-12. DOI: 10.3389/fimmu.2020.01945

Federici C, Shahaj E, Cecchetti S, Camerini S, Casella M, Lessi E, et al. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. Front Immunol. 2020; 11(262):1-24. DOI: 10.3389/fimmu.2020.00262

Xu Y, Zhou S, Lam Y, Pang S. Dynamics of Natural Killer Cells Cytotoxicity in Microwell Arrays with Connecting Channels. Front Immunol. 2017; 8(998):1-9. DOI: 10.3389/fimmu.2017.00998

Mantesso S, Geerts D, Spanholtz J, Kučerová. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Front Immunol. 2020; 11(607131):1-12. DOI: 10.3389/fimmu.2020.607131

Terrén I, Orrantia A, Vitallé J, Zenarruzabeitia O, Borrego F. NK Cell Metabolism and Tumor Microenvironment. Front Immunol. 2019; 10(2278):1-9. DOI: 10.3389/fimmu.2019.02278

Morrissey M, Williamson A, Steinbach A, Roberts E, Kern N, Headley M, et al. Chimeric antigen receptor that trigger phagocytosis. eLife. 2018; 7(e36688):1-21. DOI: 10.7554/eLife.36688

Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Letters. 2020; 472:175-180. DOI: 10.1016/j.canlet.2019.11.033

Esteso G, Aguiló N, Julián E, Ashiru O, Ho M, Martín C, et al. Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG. Front Immunol. 2021; 12(622995):1-11. DOI: 10.3389/fimmu.2021.622995

Feins S, Kong W, Williams E, Milone M, Fraietta J. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019; 94:S3-S9. DOI: 10.1002/ajh.25418

Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of Chimeric Receptor Composed Of Immunoglobulin-Derived V Regions And T-cell Receptor-Derived C Regions. Biochem Biophys Res Commun. 1987; 149(3):960-968. DOI: 0006-291X/87.

Irving BA, Weiss A. The Cytoplasmic Domain of the T cell Receptor ζ Chain is Sufficient to Couple to Receptor-Associated Signal Transduction Pathways. Cell. 1991; 64(5):891-901. DOI: 10.1016/0092-8674(91)90314-o

Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol Cancer Ther. 2018; 17(9):1795-1815. doi: 10.1158/1535-7163.MCT-17-1097

Liu E, Marin D, Banerjee P, Macapinlac H, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020; 382:545-53. DOI: 10.1056/NEJMoa1910607

Xia J, Minamino S, Kuwabara K. CAR-expressing NK cells for cancer therapy: a new hope. BioScience Trends. 2020; 14(5):354-359. DOI: 10.5582/bst.2020.03308

Bergman H, Sissala N, Hägerstrand H, Lindqvist C. Human NK-92 Cells Function as Target Cells for Human NK Cells – Implications for CAR NK-92 Therapies. Anticancer Research. 2020; 40:5355-5359. DOI: 10.21873/anticanres.14543

Zhao S, Han Z, Ji C, An G, Meng H, Yang L. The research significance of concomitant use of CAR-CD138-NK and CAR-CD19-NK to target multiple myelomas. European Journal of Inflammation. 2018; 16:1-9 DOI: 10.1177/2058739218788968

Zhao Z, Chen Y, Francisco N, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges. APSB 2018; 8(4):539–551.

Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021. DOI: 10.1038/s41434-021-00246-w

Jayaraman J, Mellody M, Hou A, Desai R, Fung A, Huynh A, et al. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020; 8(102931) DOI: 10.1016/j.ebiom.2020.102931

Pfefferle A, Huntington N. You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. Cancers. 2020; 12(706):1-23 DOI:10.3390/cancers12030706

Franks S, Wolfson B, Hodge J. Natural Born Killers: NK Cells in Cancer Therapy. Cancers. 2020; 12(2131):1-21. DOI: 10.3390/cancers12082131

Gang M, Marin N, Wong P, Neal C, Marsala L, Foster M, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020; 136(20): 2308-2318. DOI: 10.1182/blood.2020006619

Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y, et al. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model. Cytotherapy. 2020;22:552-562. DOI: 10.1016/j.jcyt.2020.06.003

Li Y, Hermanson D, Moriarity B, Kaufman D. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018; 23:181-192. DOI: 10.1016/j.stem.2018.06.002

Peng X, Chen L, Chen L, Wang B, Wang Y, Zhan X. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review). Experimental and Therapeutic Medicine. 2021; 21(340): 1-7. DOI: 10.3892/etm.2021.9771

United States National Library of Medicine. Clinical Trials [Internet]. Estados Unidos: NIH; [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/

Del Zotto G, Marcenaro E, Vacca P, Sivori S, Penade D, Della M, et al. Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B (Clinical Cytometry). 2017;92B:100-114 DOI: 10.1002/cyto.b.21508

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 8 Sep 2016 - Identifier NCT02892695, PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma; 8 Sep 2016 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02892695

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 25 Oct 2016 - Identifier NCT02944162, CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML; 25 Sep 2016 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02944162

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 17 Feb 2017 - Identifier NCT03056339, Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies; 17 Sep 2017 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03056339

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 9 Jul 2018 - Identifier NCT03579927, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma; 9 Jul 2017 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03579927

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 1 Oct 2018 - Identifier NCT03690310, Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma; 1 Oct 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03690310

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2 Oct 2018 - Identifier NCT03692767, Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma; 2 Oct 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03692767

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 31 Ene 2019 - Identifier NCT03824964, Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma; 31 May 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03824964

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 7 May 2019 - Identifier NCT03940833, Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM; 7 May 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03940833

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 10 Nov 2020 - Identifier NCT04623944, Safety of Intravenous Allogeneic Engineered Natural Killer Cells in Adults With AML or MDS; 10 Nov 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04623944

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 20 Nov 2020 - Identifier NCT04639739, Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma; 20 Nov 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04639739

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 16 Mar 2021 - Identifier NCT04796675, Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies; 16 Mar 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04796675

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 16 Mar 2021 - Identifier NCT04796688, Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies; 16 Mar 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04796688

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 30 Ene 2020 - Identifier NCT03415100, Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours; 30 Ene 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03415100

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2 Oct 2018 - Identifier NCT03692663, Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer; 2 Oct 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03692663

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2 Oct 2018 - Identifier NCT03692637, Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer; 2 Oct 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03692637

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 30 Abr 2019 - Identifier NCT03931720, Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor; 30 Abr 2019 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03931720

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 7 May 2019 - Identifier NCT03940820, Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors; 7 May 2019 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03940820

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 8 May 2019 - Identifier NCT03941457, Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer; 8 May 2019 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03941457

Klingemann H, Boissel L, Toneguzzo F. Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells. Front. Immunol. 7:91. DOI: 10.3389/fimmu.2016.00091

Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology. 2020; 570-578. DOI: 10.1182/hematology.2020002547

Jamali A, Hadjati J, Madjd Z, Mirzaei H, Thalheimer F, Agarwal S, et al. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. Front. Immunol. 2020; 11(2028):1-13 DOI: 10.3389/fimmu.2020.02028

Ingegnere T, Mariotti F, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Front. Immunol. 2019; 10(957):1-10 DOI: 10.3389/fimmu.2019.00957

Descargas

Publicado

2021-12-30

Cómo citar

Betancourt-Plaza, J. D., & Ortega-Ávila, J. G. (2021). Células CAR-NK: Un modelo para la inmunoterapia tumoral. Revisión de la literatura. Salutem Scientia Spiritus, 7(4), 83–91. Recuperado a partir de https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/1294

Número

Sección

Revisión de la literatura